|
1
|
Delgermaa V, Takahashi K, Park EK, Le GV,
Hara T and Sorahan T: Global mesothelioma deaths reported to the
World Health Organization between 1994 and 2008. Bull World Health
Organ. 89:716–724. 724A–724C. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McDonald JC and McDonald AD: The
epidemiology of mesothelioma in historical context. Eur Respir J.
9:1932–1942. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amatya VJ, Mawas AS, Kushitani K, Mohi
El-Din MM and Takeshima Y: Differential microRNA expression
profiling of mesothelioma and expression analysis of miR-1 and
miR-214 in mesothelioma. Int J Oncol. 48:1599–1607. 2016.PubMed/NCBI
|
|
4
|
Dhanasekaran SM, Barrette TR, Ghosh D,
Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan
AM: Delineation of prognostic biomarkers in prostate cancer.
Nature. 412:822–826. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reiser-Erkan C, Erkan M, Pan Z, Bekasi S,
Giese NA, Streit S, Michalski CW, Friess H and Kleeff J:
Hypoxia-inducible protooncogene Pim-1 is a prognostic marker in
pancreatic ductal adenocarcinoma. Cancer Biol Ther. 7:1352–1359.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warnecke-Eberz U, Bollschweiler E, Drebber
U, Metzger R, Baldus SE, Hölscher AH and Mönig S: Prognostic impact
of protein overexpression of the proto-oncogene PIM-1 in gastric
cancer. Anticancer Res. 29:4451–4455. 2009.PubMed/NCBI
|
|
7
|
Herzog S, Fink MA, Weitmann K, Friedel C,
Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, et
al: Pim1 kinase is upregulated in glioblastoma multiforme and
mediates tumor cell survival. Neuro Oncol. 17:223–242. 2015.
View Article : Google Scholar :
|
|
8
|
Magnuson NS, Wang Z, Ding G and Reeves R:
Why target PIM1 for cancer diagnosis and treatment? Future Oncol.
6:1461–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Usami N, Fukui T, Kondo M, Taniguchi T,
Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, et al:
Establishment and characterization of four malignant pleural
mesothelioma cell lines from Japanese patients. Cancer Sci.
97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lamprecht MR, Sabatini DM and Carpenter
AE: CellProfiler: Free, versatile software for automated biological
image analysis. Biotechniques. 42:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gebäck T, Schulz MM, Koumoutsakos P and
Detmar M: TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques.
46:265–274. 2009.PubMed/NCBI
|
|
12
|
Hasegawa S, Okada M, Tanaka F, Yamanaka T,
Soejima T, Kamikonya N, Tsujimura T, Fukuoka K, Yokoi K and Nakano
T: Trimodality strategy for treating malignant pleural
mesothelioma: Results of a feasibility study of induction
pemetrexed plus cisplatin followed by extrapleural pneumonectomy
and post- operative hemithoracic radiation (Japan Mesothelioma
Interest Group 0601 Trial). Int J Clin Oncol. 21:523–530. 2016.
View Article : Google Scholar
|
|
13
|
Kapeles M, Gensheimer MF, Mart DA, Sottero
TL, Kusano AS, Truong A, Farjah F, Laramore GE, Stelzer KJ and
Patel SA: Trimodality treatment of malignant pleural mesothelioma:
An Institutional Review. Am J Clin Oncol. Aug 27–2015.Epub ahead of
print. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krug LM, Pass HI, Rusch VW, Kindler HL,
Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K,
Monberg M, et al: Multicenter phase II trial of neoadjuvant
pemetrexed plus cisplatin followed by extrapleural pneumonectomy
and radiation for malignant pleural mesothelioma. J Clin Oncol.
27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montanaro F, Rosato R, Gangemi M, Roberti
S, Ricceri F, Merler E, Gennaro V, Romanelli A, Chellini E,
Pascucci C, et al: Survival of pleural malignant mesothelioma in
Italy: A population-based study. Int J Cancer. 124:201–207. 2009.
View Article : Google Scholar
|
|
16
|
Marinaccio A, Montanaro F, Mastrantonio M,
Uccelli R, Altavista P, Nesti M, Costantini AS and Gorini G:
Predictions of mortality from pleural mesothelioma in Italy: A
model based on asbestos consumption figures supports results from
age-period- cohort models. Int J Cancer. 115:142–147. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amatya VJ, Takeshima Y, Kushitani K,
Yamada T, Morimoto C and Inai K: Overexpression of CD26/DPPIV in
mesothelioma tissue and mesothelioma cell lines. Oncol Rep.
26:1369–1375. 2011.PubMed/NCBI
|
|
18
|
Aoe K, Amatya VJ, Fujimoto N, Ohnuma K,
Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, et al:
CD26 overexpression is associated with prolonged survival and
enhanced chemosensitivity in malignant pleural mesothelioma. Clin
Cancer Res. 18:1447–1456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inamoto T, Yamada T, Ohnuma K, Kina S,
Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H,
et al: Humanized anti-CD26 monoclonal antibody as a treatment for
malignant mesothelioma tumors. Clin Cancer Res. 13:4191–4200. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thompson MA, Ohnuma K, Abe M, Morimoto C
and Dang NH: CD26/dipeptidyl peptidase IV as a novel therapeutic
target for cancer and immune disorders. Mini Rev Med Chem.
7:253–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bickel A, Koneth I, Enzler-Tschudy A,
Neuweiler J, Flatz L and Früh M: Pembrolizumab-associated minimal
change disease in a patient with malignant pleural mesothelioma.
BMC Cancer. 16:6562016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimizu T, Fukuoka K, Takeda M, Iwasa T,
Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, et
al: A first-in-Asian phase 1 study to evaluate safety,
pharmacokinetics and clinical activity of VS-6063, a focal adhesion
kinase (FAK) inhibitor in Japanese patients with advanced solid
tumors. Cancer Chemother Pharmacol. 77:997–1003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wheatley-Price P, Chu Q, Bonomi M, Seely
J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, et al: A
Phase II study of PF-03446962 in patients with advanced malignant
pleural mesothelioma. CCTG Trial IND207. J Thorac Oncol.
11:2018–2021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao J and Feng SS: Nanocarriers for
delivery of siRNA and co-delivery of siRNA and other therapeutic
agents. Nanomedicine (Lond). 10:2199–2228. 2015. View Article : Google Scholar
|
|
25
|
Kanasty R, Dorkin JR, Vegas A and Anderson
D: Delivery materials for siRNA therapeutics. Nat Mater.
12:967–977. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z
and Qiu S: Overexpression of Pim-1 in bladder cancer. J Exp Clin
Cancer Res. 29:1612010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peltola K, Hollmen M, Maula SM, Rainio E,
Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen
PJ, et al: Pim-1 kinase expression predicts radiation response in
squamocellular carcinoma of head and neck and is under the control
of epidermal growth factor receptor. Neoplasia. 11:629–636. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amaravadi R and Thompson CB: The survival
kinases Akt and Pim as potential pharmacological targets. J Clin
Invest. 115:2618–2624. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang H, Hittelman W and Nagarajan L:
Ubiquitous expression and cell cycle regulation of the protein
kinase PIM-1. Arch Biochem Biophys. 330:259–265. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttranscriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Block KM, Hanke NT, Maine EA and Baker AF:
IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell
lines. Pancreas. 41:773–781. 2012.PubMed/NCBI
|
|
32
|
Mondello P, Cuzzocrea S and Mian M: Pim
kinases in hematological malignancies: Where are we now and where
are we going? J Hematol Oncol. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
